JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 102 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $142,820 | +143.6% | 77,200 | +46.2% | 0.00% | – |
Q4 2022 | $58,626 | -74.2% | 52,816 | -45.5% | 0.00% | -100.0% |
Q3 2022 | $227,000 | -43.7% | 96,974 | -27.1% | 0.00% | 0.0% |
Q2 2022 | $403,000 | -8.8% | 133,085 | +104.3% | 0.00% | 0.0% |
Q1 2022 | $442,000 | -83.4% | 65,138 | -79.6% | 0.00% | -83.3% |
Q4 2021 | $2,660,000 | +60.6% | 318,551 | +42.9% | 0.01% | +50.0% |
Q3 2021 | $1,656,000 | -18.2% | 222,903 | -25.1% | 0.00% | -20.0% |
Q2 2021 | $2,024,000 | +107.8% | 297,629 | +213.8% | 0.01% | +66.7% |
Q1 2021 | $974,000 | -10.0% | 94,849 | -23.5% | 0.00% | 0.0% |
Q4 2019 | $1,082,000 | +481.7% | 123,919 | +121.8% | 0.00% | +200.0% |
Q3 2019 | $186,000 | -60.5% | 55,861 | -41.3% | 0.00% | -50.0% |
Q2 2019 | $471,000 | -61.1% | 95,134 | -51.3% | 0.00% | -50.0% |
Q1 2019 | $1,211,000 | -10.6% | 195,258 | -51.4% | 0.00% | -20.0% |
Q4 2018 | $1,355,000 | -35.1% | 401,932 | +25.2% | 0.01% | -16.7% |
Q3 2018 | $2,087,000 | +34.0% | 321,069 | +58.0% | 0.01% | +20.0% |
Q2 2018 | $1,557,000 | – | 203,229 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 10,230,349 | $63,428,000 | 41.36% |
TRV GP III, LLC | 3,048,780 | $18,902,000 | 9.26% |
Omega Fund Management, LLC | 1,059,930 | $6,572,000 | 1.39% |
Alambic Investment Management, L.P. | 50,622 | $314,000 | 0.13% |
Spark Investment Management LLC | 244,300 | $1,514,000 | 0.07% |
ALGERT GLOBAL LLC | 14,182 | $88,000 | 0.05% |
Redmile Group, LLC | 254,590 | $1,578,000 | 0.05% |
Granahan Investment Management | 125,533 | $778,000 | 0.04% |
GSA CAPITAL PARTNERS LLP | 38,602 | $239,000 | 0.02% |
Frontier Wealth Management LLC | 27,099 | $168,000 | 0.02% |